Oct 23, 2018 Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical ... Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical …The results were presented at the 2018 American Neurological Association Annual Meeting being held in Atlanta, Georgia. The primary objective of ... read morePublished on 2018-10-23